Welcome to our dedicated page for ViewRay news (Ticker: VRAY), a resource for investors and traders seeking the latest updates and insights on ViewRay stock.
ViewRay, Inc. (Nasdaq: VRAY) is a trailblazer in the field of MRI-guided adaptive radiotherapy. The company designs, manufactures, and markets the MRIdian® radiation therapy system, an innovative solution aimed at addressing the key limitations of conventional external-beam radiation therapy technologies. Using cutting-edge MRI-based technology, the MRIdian system provides real-time imaging that precisely distinguishes the targeted tumor from surrounding soft tissue and critical organs during radiation treatment.
One of the standout features of the MRIdian system is its capability to record the level of radiation exposure the tumor receives and adapt the treatment prescription as needed. This adaptive approach enhances the safety and efficacy of radiation therapy, which ViewRay believes will lead to better patient outcomes.
ViewRay has established itself as a visionary in the medical field, dedicated to providing doctors with advanced tools to improve cancer treatment through radiation therapy. The company prides itself on its entrepreneurial spirit and unwavering commitment to innovation and excellence.
Among its recent achievements, ViewRay announced that the VA Oklahoma City Healthcare System has selected the MRIdian system to expand its radiation therapy services. This marks the first cancer center in Oklahoma to offer Veterans access to MRIdian's advanced MRI-guided radiation therapy. The system will enable precision treatment for various cancers, including pancreas, prostate, lung, liver, breast, and oligometastatic disease.
The Veterans Health Administration, the largest integrated healthcare system in America, is actively incorporating MRIdian technology across multiple VA medical centers. This expansion highlights the growing recognition of MRIdian's short-course non-invasive therapy, which promises fewer side effects and improved quality of life for patients.
To date, over 31,000 patients worldwide have been treated using MRIdian systems, with 62 installations in hospitals across the globe. These systems are employed to treat a diverse range of solid tumors and are subjects of numerous ongoing research studies. The MRIdian system has been featured in hundreds of peer-reviewed publications and scientific presentations, underscoring its clinical significance and impact.
For a list of treatment centers utilizing MRIdian technology, visit ViewRay's website.
ViewRay, Inc. (NASDAQ: VRAY) announced a significant contract with the University Hospital Halle (Saale) in Germany for the provision of its MRIdian MRI-guided radiation therapy system. This system enhances the hospital's capabilities in treating various cancers with stereotactic body radiotherapy (SBRT). Prof. Dirk Vordermark highlighted the advantages of MRIdian's real-time tissue tracking and clinical evidence. With nearly 18,000 patients treated globally using MRIdian, the hospital aims to broaden access to personalized cancer care in Southern Saxony-Anhalt.
ViewRay, Inc. (NASDAQ: VRAY) announced its participation in the B. Riley Securities Oncology Conference on January 28, 2022, at 1:00 p.m. ET. CEO Scott Drake and CFO Zach Stassen will engage in a fireside chat during the event. Investors can access an audio webcast of the presentation on the investor relations section of the company's website, with a replay available for seven days post-event. ViewRay specializes in MR-guided radiation therapy with its MRIdian system, designed to enhance radiation oncology workflows.
ViewRay, Inc. (Nasdaq: VRAY) announced preliminary financial results for Q4 and full year 2021. The company secured seven new orders for MRIdian systems worth approximately $41 million, a significant increase from five orders totaling $24 million in Q4 2020. Full year revenue reached $70 million, up from $57 million in 2020. The total backlog rose to approximately $313 million as of December 31, 2021. Cash and cash equivalents stood at $220 million. The results are unaudited and may be subject to change.
ViewRay, Inc. (NASDAQ: VRAY) announced its participation in the 40th Annual J.P. Morgan Healthcare Conference, set for 10:30 a.m. Eastern Time on January 13, 2022. An audio webcast of the presentation will be available on ViewRay's investor website. ViewRay specializes in the MRIdian® MR-Guided Radiation Therapy System, designed to address specific challenges in radiation oncology, including issues related to high magnetic fields and radiation beams. More information can be found on their investor events page.
ViewRay, Inc. (NASDAQ: VRAY) announced FDA 510(k) clearance for its MRIdian A3i, enhancing on-table adaptive workflow and clinical utility. Key features include auto-contouring, auto-adapting, and auto-gating functionalities that aim to reduce treatment times and improve patient throughput. The system now also offers a new brain treatment package for cranial stereotactic radiosurgery. Over 16,000 patients have been treated with MRIdian, which is currently in use at 46 hospitals worldwide, providing real-time tracking and reduced radiation exposure for patients.
ViewRay, Inc. (NASDAQ: VRAY) announced that Northside Hospital in Georgia has chosen the MRIdian MRI-guided radiation therapy system to enhance its Cancer Institute's treatment services. This installation marks a significant advancement in cancer care, allowing for personalized and precision medicine. The MRIdian system enables real-time tracking of tumors and minimizes radiation exposure to surrounding healthy tissue. Northside Hospital is a leader in cancer treatment in Georgia, with a comprehensive network of over 55 cancer centers. This milestone could improve treatment options for patients in the southeast.
ViewRay, Inc. (NASDAQ: VRAY) has treated over 2,300 pancreatic cancer patients utilizing the MRIdian system at 46 centers globally, marking significant advancements during Pancreatic Cancer Awareness Month. A recent study at ASTRO 2021 indicated a median survival of 26 months for patients treated with MRIdian SMART, compared to 12-15 months with traditional therapies. The ongoing MRIdian SMART pancreas trial aims to validate these findings further. ViewRay emphasizes its commitment to improving treatment options and outcomes for patients with pancreatic cancer.
ViewRay, Inc. (Nasdaq: VRAY) announced the closing of 1,875,000 additional shares of common stock, following the full exercise of underwriters' options related to its public offering. This results in total gross proceeds of $80.5 million, including $10.5 million from the final tranche. The net proceeds will be allocated for general corporate purposes, covering working capital, capital expenditures, and ongoing R&D. The offering was managed by Piper Sandler, Stifel, and Guggenheim Securities, with registration filed with the SEC.
ViewRay, Inc. (Nasdaq: VRAY) has completed a public offering of 12,500,000 shares of common stock at $5.60 per share, generating approximately $70.0 million before expenses. All shares were sold by ViewRay, with underwriters granted an option to purchase an additional 1,875,000 shares. The proceeds are intended for general corporate purposes, including working capital and research and development. Piper Sandler and Stifel are the joint book-running managers of the offering. This offering's registration statement was effective upon filing with the SEC.
ViewRay, Inc. (Nasdaq: VRAY) announced a public offering of 12,500,000 shares of common stock priced at $5.60 per share, aiming to raise $70 million in gross proceeds. The offering will close on or about November 19, 2021, subject to closing conditions. ViewRay plans to utilize the proceeds for general corporate purposes, including working capital, capital expenditures, and ongoing R&D. The underwriting team includes Piper Sandler and Stifel, among others. There is also a 30-day option for underwriters to purchase an additional 1,875,000 shares.
FAQ
What does ViewRay, Inc. specialize in?
What is the MRIdian® system?
What recent achievement has ViewRay announced?
How many patients have been treated with the MRIdian system?
How many MRIdian systems are currently installed worldwide?
What types of cancer can be treated with MRIdian?
Why is MRIdian considered advanced in radiation therapy?
What are some common side effects of radiation therapy with MRIdian?
Is MRIdian suitable for all patients?
Where can I find more information about MRIdian treatment centers?
